May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Combined Intravitreal Bevacizumab and Triamcinolone for Exudative Age-Related Macular Degeneration
Author Affiliations & Notes
  • I. Kreissig
    Ophthalmology, Fac Clin Med Mannheim-Heidelberg, Mannheim, Germany
  • T. Libondi
    Ophthalmology, Faculty of Medicine and Surgery, II. Univ. of Naples, Naples, Italy
  • L. Golubkina
    Ophthalmology, Fac Clin Med Mannheim-Heidelberg, Mannheim, Germany
  • U. H. Spandau
    Ophthalmology, Fac Clin Med Mannheim-Heidelberg, Mannheim, Germany
  • F. Schlichtenbrede
    Ophthalmology, Fac Clin Med Mannheim-Heidelberg, Mannheim, Germany
  • F. Rensch
    Ophthalmology, Fac Clin Med Mannheim-Heidelberg, Mannheim, Germany
  • J. B. Jonas
    Ophthalmology, Fac Clin Med Mannheim-Heidelberg, Mannheim, Germany
  • Footnotes
    Commercial Relationships  I. Kreissig, None; T. Libondi, None; L. Golubkina, None; U.H. Spandau, None; F. Schlichtenbrede, None; F. Rensch, None; J.B. Jonas, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 561. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      I. Kreissig, T. Libondi, L. Golubkina, U. H. Spandau, F. Schlichtenbrede, F. Rensch, J. B. Jonas; Combined Intravitreal Bevacizumab and Triamcinolone for Exudative Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2008;49(13):561. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To report on the combined application of intravitreal bevacizumab and triamcinolone acetonide as treatment for exudative age-related macular degeneration.

Methods: : Clinical interventional case-series includes 14 patients (14 eyes) with exudative age-related macular degeneration who had previously received 3.7 ± 1.9 mono-injections of bevacizumab (1.5 mg) without improvement of visual acuity or reduction of macular exudation. All patients underwent a combined intravitreal injection of bevacizumab (1.5 mg) and triamcinolone acetonide (about 20 mg). Main outcome measures were: visual acuity and macular thickness as determined by optical coherence tomography. All patients were re-examined at 2 to 3 months after the intervention.

Results: : Visual acuity improved significantly (P=0.008) from 0.81±0.43 logMAR prior to the combined injection to 0.67±0.41 log MAR. An improvement of at least 1 Snellen line was found in 10 (71%) patients, an increase of at least 2 lines in 5 (36%) patients, and an improvement of 3 or more lines in 1 (7%) patient. One patient (7%) lost 1 line. The central retinal thickness decreased significantly from 255 ± 59 µm to 224 ± 45 µm (P=0.03).

Conclusions: : The combined intravitreal application of bevacizumab and triamcinolone might be favourable in the treatment of exudative age-related macular degeneration, if preceding intravitreal bevacizumab mono-injections failed to improve visual acuity and reduce macular edema.

Keywords: age-related macular degeneration • visual acuity • injection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×